Annovis Bio Corrects Audit Fee Disclosures in SEC Filing
Annovis Bio, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on October 19, 2026, to correct a typographical error in its proxy statement for the annual meeting of stockholders held on June 17, 2026. The correction specifically addresses the disclosure of audit fees paid to Ernst & Young LLP. The company, headquartered at 101 Lindenwood Drive, Suite 225, in Malvern, Pennsylvania, identified the error as the reason for the additional filing.
Annovis Bio, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on October 19, 2026, to correct a typographical error in its proxy statement for the annual meeting of stockholders held on June 17, 2026. The correction specifically addresses the disclosure of audit fees paid to Ernst & Young LLP. The company, headquartered at 101 Lindenwood Drive, Suite 225, in Malvern, Pennsylvania, identified the error as the reason for the additional filing.
The corrected figures show that Annovis Bio paid Ernst & Young LLP total fees of $515,000 for fiscal year 2025. This amount is composed of $415,000 in audit fees and $100,000 in audit-related fees. The company reported no tax fees or other fees for the 2025 period. In comparison, the total fees paid to Ernst & Young LLP for fiscal year 2024 were $482,045. This prior-year total included $375,000 in audit fees and $107,045 in audit-related fees, with no amounts reported for tax or other categories.
Maria Maccecchini, Chief Executive Officer of Annovis Bio, Inc., signed the report on behalf of the registrant. The company is incorporated in Delaware and trades under the symbol ANVS on the New York Stock Exchange. Its common stock has a par value of $0.0001 per share. The filing includes an interactive data file embedded within the Inline XBRL document as Exhibit 104.